PLN 2.98
(-0.83%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 822.22 Million PLN | 1.47% |
2022 | 810.32 Million PLN | -6.34% |
2021 | 865.18 Million PLN | -0.22% |
2020 | 867.1 Million PLN | -1.62% |
2019 | 881.41 Million PLN | -12.73% |
2018 | 1.01 Billion PLN | -11.55% |
2017 | 1.14 Billion PLN | -11.83% |
2016 | 1.29 Billion PLN | 3.61% |
2015 | 1.25 Billion PLN | -36.02% |
2014 | 1.95 Billion PLN | 3.34% |
2013 | 1.89 Billion PLN | -1.28% |
2012 | 1.91 Billion PLN | -5.4% |
2011 | 2.02 Billion PLN | 28.0% |
2010 | 1.58 Billion PLN | -1.44% |
2009 | 1.6 Billion PLN | -22.28% |
2008 | 2.06 Billion PLN | 33.54% |
2007 | 1.54 Billion PLN | 55.92% |
2006 | 991.63 Million PLN | 176.9% |
2005 | 358.12 Million PLN | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 799.05 Million PLN | 0.26% |
2024 Q1 | 796.99 Million PLN | -3.07% |
2023 FY | 822.22 Million PLN | 1.47% |
2023 Q1 | 815.91 Million PLN | 0.69% |
2023 Q3 | 823.19 Million PLN | 0.53% |
2023 Q2 | 818.87 Million PLN | 0.36% |
2023 Q4 | 822.22 Million PLN | -0.12% |
2022 Q2 | 829.76 Million PLN | -1.52% |
2022 Q1 | 842.58 Million PLN | -2.61% |
2022 FY | 810.32 Million PLN | -6.34% |
2022 Q4 | 810.32 Million PLN | -3.97% |
2022 Q3 | 843.85 Million PLN | 1.7% |
2021 FY | 865.18 Million PLN | -0.22% |
2021 Q2 | 854.95 Million PLN | -0.43% |
2021 Q1 | 858.61 Million PLN | -0.98% |
2021 Q3 | 866.05 Million PLN | 1.3% |
2021 Q4 | 865.18 Million PLN | -0.1% |
2020 FY | 867.1 Million PLN | -1.62% |
2020 Q2 | 884.96 Million PLN | -0.63% |
2020 Q3 | 880.05 Million PLN | -0.55% |
2020 Q4 | 867.1 Million PLN | -1.47% |
2020 Q1 | 890.6 Million PLN | 1.04% |
2019 FY | 881.41 Million PLN | -12.73% |
2019 Q1 | 1.03 Billion PLN | 2.35% |
2019 Q2 | 907.16 Million PLN | -12.24% |
2019 Q3 | 914.17 Million PLN | 0.77% |
2019 Q4 | 881.41 Million PLN | -3.58% |
2018 FY | 1.01 Billion PLN | -11.55% |
2018 Q4 | 1.01 Billion PLN | -5.75% |
2018 Q1 | 1.11 Billion PLN | -2.11% |
2018 Q2 | 1.14 Billion PLN | 2.4% |
2018 Q3 | 1.07 Billion PLN | -6.38% |
2017 Q4 | 1.14 Billion PLN | -1.12% |
2017 Q2 | 1.16 Billion PLN | -5.48% |
2017 Q1 | 1.23 Billion PLN | -4.57% |
2017 FY | 1.14 Billion PLN | -11.83% |
2017 Q3 | 1.15 Billion PLN | -1.14% |
2016 Q3 | 1.25 Billion PLN | -0.84% |
2016 Q1 | 1.22 Billion PLN | -2.15% |
2016 FY | 1.29 Billion PLN | 3.61% |
2016 Q2 | 1.26 Billion PLN | 3.11% |
2016 Q4 | 1.29 Billion PLN | 3.56% |
2015 Q1 | 1.98 Billion PLN | 1.67% |
2015 FY | 1.25 Billion PLN | -36.02% |
2015 Q4 | 1.25 Billion PLN | -37.84% |
2015 Q3 | 2.01 Billion PLN | 0.35% |
2015 Q2 | 2 Billion PLN | 0.87% |
2014 Q3 | 1.97 Billion PLN | 3.5% |
2014 Q4 | 1.95 Billion PLN | -0.92% |
2014 Q2 | 1.9 Billion PLN | -0.75% |
2014 FY | 1.95 Billion PLN | 3.34% |
2014 Q1 | 1.91 Billion PLN | 1.54% |
2013 Q3 | 1.92 Billion PLN | -1.48% |
2013 Q4 | 1.89 Billion PLN | -1.85% |
2013 FY | 1.89 Billion PLN | -1.28% |
2013 Q1 | 1.96 Billion PLN | 2.59% |
2013 Q2 | 1.95 Billion PLN | -0.49% |
2012 Q3 | 2 Billion PLN | -2.63% |
2012 Q1 | 2.02 Billion PLN | 0.26% |
2012 Q4 | 1.91 Billion PLN | -4.58% |
2012 FY | 1.91 Billion PLN | -5.4% |
2012 Q2 | 2.06 Billion PLN | 1.56% |
2011 Q3 | 1.76 Billion PLN | 11.29% |
2011 Q4 | 2.02 Billion PLN | 14.72% |
2011 FY | 2.02 Billion PLN | 28.0% |
2011 Q1 | 1.55 Billion PLN | -1.85% |
2011 Q2 | 1.58 Billion PLN | 2.16% |
2010 Q2 | 1.56 Billion PLN | -2.8% |
2010 Q1 | 1.6 Billion PLN | 0.3% |
2010 FY | 1.58 Billion PLN | -1.44% |
2010 Q4 | 1.58 Billion PLN | 3.56% |
2010 Q3 | 1.52 Billion PLN | -2.38% |
2009 Q4 | 1.6 Billion PLN | 0.0% |
2009 FY | 1.6 Billion PLN | -22.28% |
2008 FY | 2.06 Billion PLN | 33.54% |
2007 FY | 1.54 Billion PLN | 55.92% |
2006 FY | 991.63 Million PLN | 176.9% |
2005 FY | 358.12 Million PLN | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Bioceltix S.A. | 12.73 Million PLN | -6356.262% |
Captor Therapeutics Spolka Akcyjna | 97.29 Million PLN | -745.092% |
Mabion S.A. | 208.25 Million PLN | -294.818% |
Molecure S.A. | 168.57 Million PLN | -387.742% |
NanoGroup S.A. | 8.63 Million PLN | -9425.759% |
Pharmena S.A. | 24.13 Million PLN | -3307.194% |
Poltreg S.A. | 127.09 Million PLN | -546.921% |
Pure Biologics SpĆ³lka Akcyjna | 22.73 Million PLN | -3516.079% |
Ryvu Therapeutics S.A. | 403.2 Million PLN | -103.924% |
Synthaverse S.A. | 265.9 Million PLN | -209.22% |
Urteste S.A. | 29.59 Million PLN | -2677.971% |